Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NeuroMetrix Inc NURO

Healthcare Medical Devices
NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two... see more

Recent & Breaking News (NDAQ:NURO)

NeuroMetrix Reports Q2 2022 Financial Results

GlobeNewswire July 21, 2022

NeuroMetrix, Inc. Announces Date for Second Quarter 2022 Financial Results Conference Call

GlobeNewswire July 14, 2022

NeuroMetrix Appoints Brad Fluegel to its Board of Directors

GlobeNewswire June 28, 2022

NeuroMetrix Reports that Quell® Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia

GlobeNewswire May 19, 2022

NeuroMetrix Reports Q1 2022 Financial Results

GlobeNewswire April 26, 2022

NeuroMetrix, Inc. Announces Date for First Quarter 2022 Financial Results Conference Call

GlobeNewswire April 19, 2022

NeuroMetrix Reports that Quell® Wearable Neuromodulator to be Evaluated in Post-Acute COVID-19 Syndrome

GlobeNewswire February 24, 2022

NeuroMetrix Reports Q4 and Full Year 2021 Financial Results

GlobeNewswire January 27, 2022

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2021 Financial Results Conference Call

GlobeNewswire January 20, 2022

NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation Technology

GlobeNewswire January 18, 2022

NeuroMetrix Names Strategic Growth Executive, Brandi Damkier, as Vice President, Clinical Partnerships

GlobeNewswire January 10, 2022

NeuroMetrix to Present at H.C. Wainwright BioConnect Conference 2022

GlobeNewswire January 5, 2022

NeuroMetrix Reports Q3 2021 Financial Results

GlobeNewswire October 21, 2021

NeuroMetrix Names Strategic Growth Executive, Susan M. Bell, RN, BN, as Senior Vice President of Population Health & Value Based Care

GlobeNewswire October 20, 2021

NeuroMetrix, Inc. Announces Date for Third Quarter 2021 Financial Results Conference Call

GlobeNewswire October 14, 2021

NeuroMetrix Announces Submission of FDA De Novo Request for Treatment of Fibromyalgia Symptoms with the Quell® Wearable Neuromodulation Device

GlobeNewswire October 6, 2021

NeuroMetrix Announces Participation in the Center to Stream Healthcare In Place (C2SHIP) as an Industry Partner

GlobeNewswire October 5, 2021

NeuroMetrix Announces Peer-Reviewed Publication of a Randomized Controlled Trial of its Wearable Neurostimulation Technology for Treatment of Fibromyalgia

GlobeNewswire July 26, 2021

NeuroMetrix Reports Q2 2021 Financial Results

GlobeNewswire July 22, 2021

NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Fibromyalgia with its Wearable Neurostimulation Technology

GlobeNewswire July 20, 2021